NutriLeads has announced the results of a recently published study which found that a carrot-derived Rhamnogalacturonan-I (cRG-I) may beneficially modulate the human gut microbiota.
NutriLeads (Wageningen, The Netherlands) has announced the results of a recently published study1 which found that a carrot-derived Rhamnogalacturonan-I (cRG-I) may beneficially modulate the human gut microbiota. cRG-I is a complex pectin-derived polysaccharide from carrot pomace, which NutriLeads markets as BeniCaros. Researchers used the SHIME in vitro dynamic model to compare the effect of the cRG-I on the fecal microbiota of four donors in parallel.
Results showed that despite interindividual variability between subjects, the administration of cRG-I consistently modified the human microbiota. Administration of cRG-I was associated with enhanced levels of acetate, propionate, and to a lesser extent, butyrate, which coincided with an increase in Operatinal Taxonomic Units (OTUs) related to Bacteroides dorei and Prevotella species.
“The results of the SHIME study are fundamental to our ongoing research into BeniCaros and the underlying mechanisms that drive its powerful immune health benefits,” said Dr. Ruud Albers, CSO of Nutrileads. “Our data shows that BeniCaros can help product manufacturers to deliver a more well-rounded immune health solution to consumers, and they will be able to feel the difference.”
BeniCaros is a soluble fiber made using a proprietary process of upcycling carrot pomace, which is a byproduct of carrot juice production. The ingredient is tasteless, odorless powder without artificial additives, making it label friendly. BeniCaros is suitable for most functional food, beverage, and supplement formats, and meets consumer demands for ingredients that support immune health. The ingredient recently won NutriLeads the Fi (Food Ingredients) Europe Innovation Award in the Health Innovation category.
Reference
Kaneka Nutrients to unveil new consumer research on menopausal women at Vitafoods Europe 2024
April 26th 2024The company will reveal the results of the research that is based on live feedback from 200 menopausal women who took 200 mg per day of Kaneka Ubiquinol over two-months, monitored the effects, and recorded their observations.
Rousselot to showcase new collagen peptide research and targeted solutions at Vitafoods Europe 2024
April 25th 2024The company will be highlighting new research that demonstrates the ability of its Peptan collagen peptide brand to support sleep quality, reduce gastrointestinal discomfort, and enhance skin health, including density, hydration, and elasticity.